Cargando…

Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers

OBJECTIVE: Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials in the USA. This may lead to misleading conclusions in race-based subgroup analyses. We conducted focus groups to evaluate the perceptions of diverse patients with l...

Descripción completa

Detalles Bibliográficos
Autores principales: Arriens, Cristina, Aberle, Teresa, Carthen, Fredonna, Kamp, Stan, Thanou, Aikaterini, Chakravarty, Eliza, James, Judith A, Merrill, Joan T, Ogunsanya, Motolani E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073780/
https://www.ncbi.nlm.nih.gov/pubmed/32201595
http://dx.doi.org/10.1136/lupus-2019-000360
_version_ 1783506696855879680
author Arriens, Cristina
Aberle, Teresa
Carthen, Fredonna
Kamp, Stan
Thanou, Aikaterini
Chakravarty, Eliza
James, Judith A
Merrill, Joan T
Ogunsanya, Motolani E
author_facet Arriens, Cristina
Aberle, Teresa
Carthen, Fredonna
Kamp, Stan
Thanou, Aikaterini
Chakravarty, Eliza
James, Judith A
Merrill, Joan T
Ogunsanya, Motolani E
author_sort Arriens, Cristina
collection PubMed
description OBJECTIVE: Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials in the USA. This may lead to misleading conclusions in race-based subgroup analyses. We conducted focus groups to evaluate the perceptions of diverse patients with lupus about clinical trial participation. METHODS: A qualitative research design employed three 90 min focus groups led by a trained moderator and guided by the Theory of Planned Behaviour. Open-ended questions about trial participation included advantages and disadvantages (behavioural beliefs), approving and disapproving significant others (normative beliefs), and participation enhancers and barriers (control beliefs). Discussions were recorded, transcribed and analysed to identify emerging themes. RESULTS: Patients with SLE (n=23) aged 21–72, with increased proportion of minority groups (65%), participated. Reported advantages of trial participation included altruism and personal benefit. Disadvantages included uncertainties, disappointment, information burden, and life–health balance. Although some patients had discussed research participation with approving or disapproving family or friends, self-approval superseded external approval. Barriers included logistics and time, and facilitators included flexibility in scheduling, advance notice of studies, streamlined forms, and hope for SLE improvement. CONCLUSIONS: Knowledge about potential benefits of clinical trial participation was high. Minority patients demonstrated confidence in making their own informed decisions, but major barriers for all participants included burdensome forms, travel, childcare, and work. These suggest a major impact on minority and all recruitment from behavioural and control aspects, which should be considered in the logistics of trial design. This does not minimise the potential importance of improved access and education about clinical research.
format Online
Article
Text
id pubmed-7073780
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-70737802020-03-20 Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers Arriens, Cristina Aberle, Teresa Carthen, Fredonna Kamp, Stan Thanou, Aikaterini Chakravarty, Eliza James, Judith A Merrill, Joan T Ogunsanya, Motolani E Lupus Sci Med Clinical Trials and Drug Discovery OBJECTIVE: Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials in the USA. This may lead to misleading conclusions in race-based subgroup analyses. We conducted focus groups to evaluate the perceptions of diverse patients with lupus about clinical trial participation. METHODS: A qualitative research design employed three 90 min focus groups led by a trained moderator and guided by the Theory of Planned Behaviour. Open-ended questions about trial participation included advantages and disadvantages (behavioural beliefs), approving and disapproving significant others (normative beliefs), and participation enhancers and barriers (control beliefs). Discussions were recorded, transcribed and analysed to identify emerging themes. RESULTS: Patients with SLE (n=23) aged 21–72, with increased proportion of minority groups (65%), participated. Reported advantages of trial participation included altruism and personal benefit. Disadvantages included uncertainties, disappointment, information burden, and life–health balance. Although some patients had discussed research participation with approving or disapproving family or friends, self-approval superseded external approval. Barriers included logistics and time, and facilitators included flexibility in scheduling, advance notice of studies, streamlined forms, and hope for SLE improvement. CONCLUSIONS: Knowledge about potential benefits of clinical trial participation was high. Minority patients demonstrated confidence in making their own informed decisions, but major barriers for all participants included burdensome forms, travel, childcare, and work. These suggest a major impact on minority and all recruitment from behavioural and control aspects, which should be considered in the logistics of trial design. This does not minimise the potential importance of improved access and education about clinical research. BMJ Publishing Group 2020-03-15 /pmc/articles/PMC7073780/ /pubmed/32201595 http://dx.doi.org/10.1136/lupus-2019-000360 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Clinical Trials and Drug Discovery
Arriens, Cristina
Aberle, Teresa
Carthen, Fredonna
Kamp, Stan
Thanou, Aikaterini
Chakravarty, Eliza
James, Judith A
Merrill, Joan T
Ogunsanya, Motolani E
Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
title Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
title_full Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
title_fullStr Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
title_full_unstemmed Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
title_short Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
title_sort lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
topic Clinical Trials and Drug Discovery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073780/
https://www.ncbi.nlm.nih.gov/pubmed/32201595
http://dx.doi.org/10.1136/lupus-2019-000360
work_keys_str_mv AT arrienscristina lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers
AT aberleteresa lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers
AT carthenfredonna lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers
AT kampstan lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers
AT thanouaikaterini lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers
AT chakravartyeliza lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers
AT jamesjuditha lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers
AT merrilljoant lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers
AT ogunsanyamotolanie lupuspatientdecisionsaboutclinicaltrialparticipationaqualitativeevaluationofperceptionsfacilitatorsandbarriers